The letter of intent submitted to the USAMRMC Breast Cancer Research Program (BCRP), "

Novel Agents for Targeting and Studying the ErbB4 Receptor Tyrosine Kinase", was not selected for further consideration.  We are disappointed in this outcome.  However, we will retool this proposal and submit it to the NIH/NCI later this year.